Stock market Updates | Suven Life Sciences Ltd. | R Wadiwala Securities Pvt Ltd
investments Associate Login Online Trading Login

We are investment service provider for Buy stocks , Low Stocks Brokerage , Stocks Portfolio Management in Surat , NRI Investment in Stocks , Share Broking Surat , Stock Broking Surat , Advisory Services Surat and Competetive Stocks Brokerage. investment advisory, financial integrity and prompt services in the whole of South Gujarat.

equity
Home Markets & NewsCompany ProfileSmart Quotes

SUVEN LIFE SCIENCES LTD.

NSE : SUVENBSE : 530239ISIN CODE : INE495B01038Industry : Pharmaceuticals & DrugsHouse : Private
BSE106.90-2.94 (-2.68 %)
PREV CLOSE (Rs.) 109.84
OPEN PRICE (Rs.) 109.00
BID PRICE (QTY) 0.00 (0)
OFFER PRICE (QTY) 0.00 (0)
VOLUME 7400
TODAY'S LOW / HIGH (Rs.)105.60 109.84
52 WK LOW / HIGH (Rs.)55.01 128.79
NSE106.15-3.85 (-3.5 %)
PREV CLOSE( Rs. ) 110.00
OPEN PRICE (Rs.) 108.90
BID PRICE (QTY) 0.00 (0)
OFFER PRICE (QTY) 106.15 (514)
VOLUME 296114
TODAY'S LOW / HIGH(Rs.) 105.00 110.50
52 WK LOW / HIGH (Rs.)55.1 129

Smart Quotes

BSE NSE
1D 1M 3M 1Y 3Y 5Y
Stock Summary
Trade Value (Rs. in Lacs)
7.91
Dividend Yield(%)
0.00
TTM EPS (Rs.)
-0.33
P/E Ratio
0.00
Book Value (Rs.)
38.92
Face Value (Rs.)
1
MCap (Rs. in Mn)
23953.22
Price/Earning (TTM)
-5085.61
Price/Sales (TTM)
200.97
Price/Book (MRQ)
2.82
PAT Margin (%)
-148.66
ROCE (%)
-2.95
company info
Incorporation Year : 09-03 1989

Management Info :

Venkateswarlu Jasti - Chairman - Managing Director

Registered Office :

Address : 8-2-334, S D E Serene Chambers,6th Floor, Road No 5, Avenue 7,Banjara Hills,
Hyderabad,
Telangana-500034

Phone : 040- 23541142 /3315 / 23543311

Email : info@suven.com

Website : www.suven.com

Registrars Details :

K FIN Technologies Ltd.-(Karvy Fintech Pvt Ltd.)
Karvy Selenium Tower B, Plot 31-32,Gachibowli,Financial District,Nanakramguda,Hyderabad
Listing : BSE, NSE, MCX
News
01Mar Suven Pharmaceuticals to merge Cohance
Suven Pharmaceuticals has proposed scheme of amalgamation to merge Cohan..
29Jan Suven Pharmaceuticals informs about bo
Suven Pharmaceuticals has informed that a Meeting of the Board of Direct..
12Jan Clarification sought from Suven Life
The Exchange has sought clarification from Suven Life Sciences Ltd on Ja..
more
Financials
QTR Dec 23 ANNUAL 23
Net Profit-47.69-201.27
Gross Profit -47.69 -201.27
Operating Profit -31.33 -192.95
Net Sales 24.51 135.39
more
Rs. in Millions
Rolling Forward P/E (EOD)
Event Calendar
peer group
Abbott India (BSE)
Rwadiwala-peer-arrow  26222.45 (0.64%)
M.Cap (Rs. in Cr)55594.55
Bharat Parenterals (BSE)
Rwadiwala-peer-arrow  1455.20 (10.00%)
M.Cap (Rs. in Cr)775.18
Solara Active Pharma (BSE)
Rwadiwala-peer-arrow  551.45 (16.32%)
M.Cap (Rs. in Cr)1886.74
Pfizer (BSE)
Rwadiwala-peer-arrow  4155.00 (1.16%)
M.Cap (Rs. in Cr)18759.54
Shareholding Pattern
PROMOTERS
69.57%
NON-INSTITUTION
28.92%
MUTUAL FUNDS/UTI
1.05%
FI/BANKS/INSURANCE
0%
GOVERNMENT
0%
FII
0%
more
Mf Holdings
ATTENTION INVESTORS|KYC|IPO|PROPRIETARY TRADING
Prevent Unauthorised transactions in your account. Update your mobile numbers/email IDs with your stock brokers. Receive information of your transactions directly from Exchange on your mobile/email at the end of the day .......... Issued in the interest of investors.    
ATTENTION INVESTORS Advisory for Investors Advisory - KYC Compliance
  • 1. Stock Brokers can accept securities as margin from clients only by way of pledge in the depository system w.e.f. September 1, 2020.
  • 2. Update your mobile number & email Id with your stock broker/depository participant and receive OTP directly from depository on your email id and/or mobile number to create pledge.
  • 3. Pay 20% upfront margin of the transaction value to trade in cash market segment.
  • 4. Investors may please refer to the Exchange's Frequently Asked Questions (FAQs) issued vide circular reference NSE/INSP/45191 dated July 31, 2020 and NSE/INSP/45534 dated August 31, 2020 and other guidelines issued from time to time in this regard.
  • 5. Check your Securities /MF/ Bonds in the consolidated account statement issued by NSDL/CDSL every month. .......... Issued in the interest of Investors
CORPORATE OFFICE
address
  • 9/2003-4,
  • Vishnu Priya Limda Chowk
  • Main Road
  • Surat – 395 003.
fax us @ +91-261-6673537
email us @ info@rwadiwala.com

Feed Back  | Terms & Conditions  | SEBI  | FMC  | NSE  | BSE  |  Advisory For Investors  |  MCX  | IRDA  |  AMFI  | Disclaimer  | Privacy Policy  | Careers | User Agreements  | Ethics Policy  | Investor Protection  |  Dos and Don'ts   |  Rights and Obligations   |  Uniform Risk Disclosure   |   Important Policies   |  Investor Charter   |  Investor Complaints   | To File A Complaint on SCORES   |   Online Dispute Resolution Portal (ODR Portal) |   CLIENT BANK ACCOUNT DETAILS  |  Sitemap 

BSE, NSE, MCX SEBI Regn no.: INZ000187332 | PMS SEBI Regn no.: INP000004045 | CDSL SEBI Regn No.: IN-DP-112-2015 | CDSL DP ID: 12043100
| R Wadiwala Securities Pvt Ltd - CIN: U67120GJ2004PTC044324

Compliance Officer - Email ID: compliance@rwadiwala.com | Contact No.: 0261-6673542

The Stock Exchange, Mumbai is not in any manner answerable, responsible or liable to any person or persons for any acts of omission or commission, errors, mistakes and/or violation, actual or perceived, by us or our partners, agents, associates etc., of any of the Rules, Regulations, Bye-laws of the Stock Exchange, Mumbai, SEBI Act or any other laws in force from time to time. The Stock Exchange, Mumbai is not answerable, responsible or liable for any information on this Website or for any services rendered by us, our employees, and our servants.

Investor Greivance Redressal at support@rwadiwala.com

Copyright © 2016 | All Rights Reserved. R.Wadiwala group.

Designed & Developed by ●●● Accord Fintech Pvt. Ltd.